Optimal dose of dasatinib determined for advanced, recurrent ovarian cancer

Share this article:

A phase I trial determined that dasatinib 150 mg daily is the optimum dose when dasatinib is combined with paclitaxel and carboplatin to treat patients with advanced or recurrent ovarian cancer.

Dasatinib is an oral SRC-family tyrosine kinase inhibitor. It has promising potential to treat advanced ovarian cancer because the SRC families play a role in the increased activation of cell migration, proliferation, survival, invasion, and angiogenesis. The SRC pathways are frequently dysregulated in solid tumors and can increase chemotherapy resistance.

Previous laboratory studies with ovarian cancer cell lines found that SRC inhibition enhanced the cytotoxic efficacy of both paclitaxel and cisplatin. Studies done in vivo found decreased tumor growth with SRC inhibition. This study sought to determine the maximum tolerated dose of dasatinib when it was combined with paclitaxel and cisplatin.

Administering dasatinib with paclitaxel did not alter the effects of either drug, according to the study's results. Further, dasatinib may be better used in combination with chemotherapy agents for a synergistic effect.

“It may also be better to combine dasatinib with only one cytotoxic therapy to improve tolerability,” study co-author Robert M. Wenham, MD, of the Moffitt Cancer Center explained.

The researchers concluded that finding biomarkers to direct the use of targeted therapies is of the utmost importance. Although SRC gene expression was not correlated with response, the research team found several differentially regulated genes between responders and those with stable disease.

“Unfortunately, a biomarker was unable to be identified to demonstrate which women are most likely to benefit from dasatinib,” said study contributor Johnathan M. Lancaster, MD, PhD, also of Moffitt Cancer Center. “Further study should explore relevant biomarkers and identify a patient population most likely to benefit from the addition of dasatinib.”

This study was published in Clinical Cancer Research (2012; doi:10.1158/1078-0432.CCR-12-0507).
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Genetic sequence of rare kidney cancer reveals unique alterations involving telomerase

An international scientific collaboration has revealed clues about genetic alterations that may contribute to a rare form of kidney cancer, providing new insights not only into this rare cancer but other types as well.

Double mastectomy rates are up, but survival is not improved

The percentage of women that underwent a double mastectomy increased substantially between 1998 and 2011, even though the procedure was not associated with a lower risk of death than breast-conserving surgery plus radiation.

Women with severe, chronic health issues undergo breast cancer screening less often ...

Women with severe disabilities and multiple chronic conditions are screened for breast cancer less often than women with no disabilities or no chronic conditions.